Affordable Access

Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.

Authors
  • Schmoll, H-J1
  • Kollmannsberger, C
  • Metzner, B
  • Hartmann, J T
  • Schleucher, N
  • Schöffski, P
  • Schleicher, J
  • Rick, O
  • Beyer, J
  • Hossfeld, D
  • Kanz, L
  • Berdel, W E
  • Andreesen, R
  • Bokemeyer, C
  • 1 Department of Hematology/Oncology, University of Halle, Halle, Germany. [email protected]
Type
Published Article
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publication Date
Nov 15, 2003
Volume
21
Issue
22
Pages
4083–4091
Identifiers
PMID: 14568987
Source
Medline
License
Unknown

Abstract

Repetitive cycles of high-dose VIP with peripheral stem cell support can be successfully applied in a multicenter setting. Dose level 6 with cisplatin 100 mg/m2, etoposide 1500 mg/m2, and ifosfamide 10 g/m2 is recommended for further investigation in randomized trials. An ongoing randomized trial within the European Organization for Research and Treatment of Cancer evaluates this protocol against four cycles of standard cisplatin, etoposide, and bleomycin.

Report this publication

Statistics

Seen <100 times